Skip to main content
Premium Trial:

Request an Annual Quote

John Bergeron, Samir Hanash, Harriss Currie, Norbert G. Riedel, Theron Odlaug, Dan Keeney, Andy Hull, Benjamin Bulkley, John Thompson

Premium

John Bergeron has been elected the next president of HUPO. Bergeron will take over for current president Samir Hanash in June 2004. The announcement was made at last week’s second annual HUPO Congress in Montreal.

Bergeron is professor and chair of the department of anatomy and cell biology at the faculty of medicine at McGill University. He is also founder, scientific advisor, and former chief scientific officer of Caprion Pharmaceuticals, and is currently the director of the Genome Quebec/Genome Canada Montreal Proteome Center (see PM 10-3-03). Bergeron holds a PhD from Oxford University, where he studied as a Rhodes Scholar.


Harriss Currie has been appointed vice president of finance and chief financial officer of Luminex. Currie has been the acting CFO and controller at the company since March 2002, and controller since 1998.


Norbert G. Riedel, Theron Odlaug, Dan Keeney, and Andy Hull have all been appointed to the board of directors of iBIO, the Illinois Biotechnology Industry Organization, iBIO said Oct. 14.

Riedel is chief scientific officer of cancer therapeutics firm Baxter International. Before joining Baxter in 1998, he served as head of biotechnology and core research at Hoechst Marion Roussel. He is also on the board of Genencor, Genome Therapeutics, and NanoMateria, and is on the board of directors of the Biotechnology Industry Organization, of which iBIO is the Illinois affiliate.

Odlaug is executive vice president of operations, administration, and strategic relations for Fujisawa Healthcare. He has been at Fujisawa’s Deerfield, Ill., office since 1992. Prior to joining Fujisawa, Odlaug was vice president of qua-lity for Miles (Bayer) in Elkhart, Indiana. He has also worked at Bayer’s headquarters in Leverkusen, Germany and at Baxter Healthcare.

Keeney is area vice president of state government affairs at GlaxoSmithKline, where he has worked since 1980.

Hull is director of business development at Takeda Pharmaceuticals North America, where he has worked since September 2002. Prior to joining Takeda, Hull worked in marketing and commercial development at Immunex for four years, and in marketing at Abbott Laboratories for 13 years.


Benjamin Bulkley has become senior vice president of commercial operations and John Thompson has become senior vice president of corporate development at Invitrogen. Bulkley was most recently vice president of global services for General Electric’s Medical Systems Information Technologies division. He holds a master’s degree in systems engineering from Gannon University in Pennsylvania, and a bachelor’s in electrical engineering from the University of Connecticut. Thompson was most recently vice president of corporate development for Invitrogen. He has a bachelor’s degree from Cleveland State University.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.